Video

Risk Assessment in Newly Diagnosed CLL

Related Videos
Andrew Hantel, MD
Jakub Svoboda, MD
Ponatinib in patients with chronic-phase chronic myeloid leukemia and the T315I mutation: 4-year results from OPTIC
Sujith Samarasinghe, MD
Comparative Efficacy of Bruton Tyrosine Kinase Inhibitors in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia: A Network Meta-Analysis
Consuelo Bertossi, MD
Michael R. Grunwald, MD, FACP
Shella Saint Fleur-Lominy, MD, PhD
Manali Kamdar, MD
Matthew Matasar, MD, chief, Division of Blood Disorders, Rutgers Cancer Institute; professor, medicine, Rutgers Robert Wood Johnson Medical School
Related Content
Consuelo Bertossi, MD, of University Hospital Ulm in Germany
June 18th 2024

TP53 Mutations Are Associated With Unfavorable Prognosis in CLL

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Stephen Opat, of Monash Health
June 17th 2024

Sonrotoclax Plus Zanubrutinib Is Safe, Efficacious in Relapsed/Refractory CLL/SLL

Matthew Lunning, DO, FACP
November 30th 2023

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

Jing-Zhou Hou, MD, PhD, of UPMC Hillman Cancer Center
June 17th 2024

Acalabrutinib and Zanubrutinib Both Best Ibrutinib in Real-World Safety and Efficacy CLL/SLL Outcomes

William Wierda, MD, PhD
June 17th 2024

Lower Tumor Burden Associated With Improved ORR With Liso-Cel in R/R CLL/SLL